A Purdue University team has discovered a new therapeutic target for triple-negative breast cancer. The research, led by Kyle Cottrell, an assistant professor of biochemistry, spotlights double-stranded ribonucleic acid (dsRNA)-binding proteins.
This article was originally published on MedicalXpress.com

